Compare BridgeBio Pharma Inc (BBIO) vs JPMorgan Equity Premium Income ETF (JEPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs JPMorgan Equity Premium Income ETF — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.36B), while JPMorgan Equity Premium Income ETF trades at $57.81. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, JPMorgan Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| BBIO | JEPI | |
|---|---|---|
Market Cap | $16.36B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $90.17 | $59.88 |
52-Week Low | $47.29 | $55.29 |
Enterprise Value | $18.14B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About JPMorgan Equity Premium Income ETF
JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →
